22 May 2013
Keywords: DBV Technologies, Viaskin, Peanut allergy, Immunotherapy
Article | 19 June 2012
French allergy specialist DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment of allergy, says that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 June 2012
21 May 2013
© 2013 thepharmaletter.com